Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group.
Karen R RabinMeenakshi DevidasZhiguo ChenLingyun JiJohn KairallaJohann K HitzlerJun J YangAndrew J CarrollNyla A HeeremaMichael J BorowitzBrent L WoodKathryn G RobertsCharles G MullighanRichard C HarveyI-Ming ChenCheryl L WillmanShalini C ReshmiJulie M Gastier-FosterDeepa BhojwaniSusan R RheingoldKelly W MaloneyLeonard A MattanoEric C LarsenReuven J SchoreMichael J BurkeWanda L SalzerNaomi J WinickWilliam L CarrollElizabeth A RaetzMignon L LohStephen P HungerAnne L AngiolilloPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.